Amoebicidal Drugs Lecturer: Danica B

Total Page:16

File Type:pdf, Size:1020Kb

Amoebicidal Drugs Lecturer: Danica B Amoebicidal Drugs Lecturer: Danica B. Quijano, MD Date Lectured: November 20, 2015 DLSHSI – College of Medicine: PHARMACOLOGY ö Ariba amoeba! Greetings from the amoebas! Yes, ö Improper hygienic practices we’re gonna be talking a lot about the amoeba o Protozoal infections are common among people but only for the Entameoba histolytica , the in underdeveloped tropical & subtropical pathologic agent responsible for the famous countries, where sanitary conditions, hygienic “amoebiasis” we have all heard about. practices, and control of the vectors of ö We will focus our discussion in the transmission are inadequate. However, with pharmacological treatment for infection caused increased world travel, protozoal diseases are by the protozoa Entamoeba histolytica. But first, no longer confined to specific geographical let’s have a glimpse of the offending pathogen. locations. ö Amoebiasis is an infection caused by the E. ö Speaking of diarrhea and travel.. histolytica likewise amoebiasis is sometimes o Good to know: I believe you have heard the incorrectly used to refer to infection with other term Traveler’s diarrhea. Its diagnosis does not amoebae, but strictly speaking it should be imply a specific organism, but Enterotoxigenic E. reserved for E. histolytica infection. coli (ETEC) is the most commonly isolated pathogen. While Backpacker’s diarrhea is also ö Entamoeba is a genus of amoeboid protozoa that known as Giardiasis or Beaver fever because live in the human intestine. giardiasis, caused by the protozoan Giardia o Some species within this genus are harmless, lamblia, frequently infects persons who spend a while others are pathogenic. lot of time camping, backpacking, or hunting, so o One, especially, has the potential to become it has gained the nicknames. dangerous, the Entamoeba histolytica. ö Worth mentioning: ö Clinical features varies from asymptomatic to an o Traveler’s diarrhea (ETEC) infectious diarrhea and the most dreaded life- o Backpacker’s diarrhea (Giardiasis) threatening fulminant colitis. ö Entamoeba histolytica is the only specie that is ö The pathogenic Entamoeba histolytica definitely associated with pathological sequelae in o Amoebiasis – disease caused by E. histolytica humans; § It is estimated that up to 15% of the world's o the other entamoebas are considered population is infected by the pathogen nonpathogenic. Entamoeba histolytica. Every year, over ö The genus Entamoeba contains many species, six 100,000 people die of the disease caused of which, reside in the human intestinal lumen by E. histolytica, amoebiasis, making it the o Entamoeba histolytica, second most common parasitic cause of o Entamoeba dispar, death, after malaria. o Entamoeba moshkovskii, § 2nd most common parasitic cause of death o Entamoeba polecki, after malaria o Entamoeba coli, § Tropical countries with poor sanitation are o Entamoeba hartmanni often hit hardest by outbreaks. ö The lifecycle of Entamoeba histolytica is pretty typical for a protozoan parasite. Just remember, we have 2 forms of the parasite: the cyst & the trophozoite. Let’s simplify further. ö Infection occurs by ingestion of cysts on fecally contaminated food or hands. o The cyst is resistant to the gastric environment and passes into small intestine where it decysts. o The metacyst divides into four and then eight amoebae which move to the large intestine. o The organisms encyst for mitosis and are passed through with feces. o There are no intermediate or reservoir hosts. ö Cysts and trophozoites are passed in feces. o Cysts are typically found in formed stool, o Trophozoites are typically found in diarrheal stool. ö Infection by Entamoeba histolytica occurs by ingestion of mature cysts in fecally contaminated food, water, or hands. ö Excystation occurs in the small intestine and trophozoites are released, which migrate to the large intestine. ö The trophozoites multiply by binary fission and produce cysts, and both stages are passed in the feces. o Because of the protection conferred by their walls, the cysts can survive days to weeks in the external environment and are responsible for transmission. o Trophozoites passed in the stool are rapidly destroyed once outside the body, and if ingested would not survive exposure to the gastric environment. 1 ö In many cases, the trophozoites remain confined to the intestinal lumen (: noninvasive infection) of individuals who are asymptomatic carriers, passing cysts in their stool. ö In some patients the trophozoites invade the intestinal mucosa (: intestinal disease), or, through the bloodstream, extraintestinal sites such as the liver, brain, and lungs (: extraintestinal disease), with resultant pathologic manifestations. ö It has been established that the invasive and noninvasive forms represent two separate species, respectively E. histolytica and E. dispar. o These two species are morphologically indistinguishable unless E. histolytica is observed with ingested red blood cells (erythrophagocystosis). ö Transmission can also occur through exposure to fecal matter during sexual contact (in which case not only cysts, but also trophozoites could prove infective) -- o These protozoa are transmitted by the fecal–oral route; high rates of oral–anal sex by MSM are considered the reason for increased rates of carriage. o Because E. histolytica is also transmitted by the fecal–oral route, MSM may also have an increased risk for E. histolytica carriage. ö Cysts, which are the round, dormant, resistant and infectious stage, are acquired by the fecal-oral route.u o Usually by drinking contaminated water. ö Once in the intestine, excystation occurs, with trophozoites emerging from the cyst. ö Trophozoites are the motile, feeding stage of Entamoeba histolytica. ö They are amorphous cells containing prominent round vacuoles that move via oozing pseudopod motion through the length of the intestine, until they reach the large intestine. o Once there, they multiply by binary fission and begin to form new cysts. ö The cyst serves as the protective coat. o These cysts are excreted in the feces, can survive outside the body for several weeks and are capable of infecting new hosts. ö The diagnosis is established by isolating E. histolytica from the feces. ö When exposed to new environments (such as temperature changes, or transit down the intestinal tract, or exposed to a chemical agent), the protozoa can secrete a protective coat and shrink into a round, armored form called the cyst. o It is this cyst form that is infective when ingested by humans. o Following ingestion, it converts back into the motile form, called the trophozoite. ö The cysts can live outside the hosts or be carried asymptomatically in the stool, while trophozoites, passed by people with invasive disease, cannot survive outside the host. ö Only ten percent of those infected with Entamoeba histolytica ever develop amoebiasis and its associated symptoms, most of which are very mild. o Within two to four weeks of exposure, you may experience brief bouts of diarrhea, accompanied by stomach cramping and abdominal pain. o During this time, you can be shedding millions of cysts ö In rare cases, without treatment, the symptoms can become more severe. ö Entamoeba histolytica is able to survive in the intestinal tract, but can also invade the cells of the intestinal lining. o The trophozoites release proteases, which are enzymes that break down protein, causing deep, painful lesions and ulcers in the intestinal lining. o What results is a more severe form of amoebiasis, called amoebic dysentery. o A patient with amoebic dysentery can experience intense abdominal pain, periodic loose stools with blood and mucus, and fever. o Weight loss and fatigue can also occur. ö If the amoebic dysentery goes untreated, it can progress to extraintestinal amoebiasis, although this is rare. o The trophozoites can migrate out of the large intestine, travel through the blood and invade other tissues, causing the same lesions found in the gut. 2 ö The liver receives blood from both systemic and portal circulations. Increased susceptibility to infections would be expected given the increased exposure to a pathogen. o However, Kupffer cells lining the hepatic sinusoids clear bacteria so efficiently that infection rarely occurs. o The predilection for the right hepatic lobe can be attributed to anatomic considerations. § The right hepatic lobe receives blood from both the superior mesenteric and portal veins, § Whereas the left hepatic lobe receives inferior mesenteric and splenic drainage. § Also the right hepatic lobe contains a denser network of biliary canaliculi and, overall, accounts for more hepatic mass. o Untreated, pyogenic liver abscess remains uniformly fatal. Sepsis, Multi-organ failure. Polymicrobial involvement is common. o Gross pathology of amebic abscess of liver. Tube of "chocolate" pus from abscess. ö E. histolytica is the causative agent of amebic dysentery. Dysentery - in Parasitology, you’ve discussed 2 bacterial agents of dysentery namely EIEC and Shigella dysenteriae. o And this one is dysentery, an amebic dysentery. o A patient infected may get the famous flask shaped ulcers in the GIT mucosa and may also have extensions into the liver although that would be a very severe complication from Entamoeba. o One of the things that you could also see in this disease is Pseudoappendicitis (you can also get pseudo appendicitis-like disease in infections caused by Yersinia enterocolitica). The characteristic “flask-shaped ulcers” of intestinal amoebiasis (enzymatic degradation)
Recommended publications
  • (Tea Tree) Oil and Dimethyl Sulfoxide (DMSO) Against Trophozoites and Cysts of Acanthamoeba Strains
    pathogens Article In Vitro Evaluation of the Combination of Melaleuca alternifolia (Tea Tree) Oil and Dimethyl Sulfoxide (DMSO) against Trophozoites and Cysts of Acanthamoeba Strains. Oxygen Consumption Rate (OCR) Assay as a Method for Drug Screening Tania Martín-Pérez *, Irene Heredero-Bermejo , Cristina Verdú-Expósito and Jorge Pérez-Serrano Department of Biomedicine and Biotechnology, Faculty of Pharmacy, University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain; [email protected] (I.H.-B.); [email protected] (C.V.-E.); [email protected] (J.P.-S.) * Correspondence: [email protected] Abstract: Ameobae belonging to the genus Acanthamoeba are responsible for the human diseases Acanthamoeba keratitis (AK) and granulomatous amoebic encephalitis (GAE). The treatment of these illnesses is hampered by the existence of a resistance stage (cysts). In an attempt to add new agents that are effective against trophozoites and cysts, tea tree oil (TTO) and dimethyl sulfoxide (DMSO), separately and in combination, were tested In Vitro against two Acanthamoeba isolates, Citation: Martín-Pérez, T.; T3 and T4 genotypes. The oxygen consumption rate (OCR) assay was used as a drug screening Heredero-Bermejo, I.; Verdú-Expósito, method, which is to some extent useful in amoebicide drug screening; however, evaluation of lethal C.; Pérez-Serrano, J. In Vitro effects may be misleading when testing products that promote encystment. Trophozoite viability Evaluation of the Combination of analysis showed that the effectiveness of the combination of both compounds is higher than when Melaleuca alternifolia (Tea Tree) Oil either compound is used alone. Therefore, the TTO alone or TTO + DMSO in combination were and Dimethyl Sulfoxide (DMSO) against Trophozoites and Cysts of an amoebicide, but most of the amoebicidal activity in the combination’s treatments seemed to be Acanthamoeba Strains.
    [Show full text]
  • 2012 Case Definitions Infectious Disease
    Arizona Department of Health Services Case Definitions for Reportable Communicable Morbidities 2012 TABLE OF CONTENTS Definition of Terms Used in Case Classification .......................................................................................................... 6 Definition of Bi-national Case ............................................................................................................................................. 7 ------------------------------------------------------------------------------------------------------- ............................................... 7 AMEBIASIS ............................................................................................................................................................................. 8 ANTHRAX (β) ......................................................................................................................................................................... 9 ASEPTIC MENINGITIS (viral) ......................................................................................................................................... 11 BASIDIOBOLOMYCOSIS ................................................................................................................................................. 12 BOTULISM, FOODBORNE (β) ....................................................................................................................................... 13 BOTULISM, INFANT (β) ...................................................................................................................................................
    [Show full text]
  • Entamoeba Histos>Fca and Entamoeba Dispar
    Entamoeba histoS>fcaand Entamoeba dispar: Mechanisms of adherence and implications for virulence Dylan Ravindran Pillai A thesis subrnitted in confonnity with the requirements for the degree of Doctor of Philosophy Institute of Medicai Science University of Toronto O Copyright Dylan R. Pillai, 2000 AcquiSiiand Acquisiins et Bblibgtaphic Services services bibliographques The author has granteci a non- L'auteur a accordé une licence non exclusive iicence allowing the exclusive pettantà la National Lïbrary of Canada to BïbIioth&pe nationale du Canada de reproduce, loan, disûibute or seil reproduire, prêter, disniiuer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfichef61m, de reproduction sur papier ou sur fotmat electronique. The author retams ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts hmit Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimes reproduced without the author's ou autrement reproduits sans son permission. autonsatioa, In 1925, Emile Brumpt had proposed the existence of two morphologically identical species, Entarnoeba hisrolylica (a human pathogen) and Entmoeba dispm (a non-pathogenic human commensal). Recent molecuiar and genetic evidence has supported the two-species concept. The pathogen relies on the galactose/N-Acetyl-O- galactosamine Iecth for adherence that leads to contact-dependent cytolysis of host target ceils, a key step in amebic vinilence. Work presented here explores the structure, fiinction, and expression of the lectin nom E-histoZyticu and E-dispar.
    [Show full text]
  • Investigating Rad51 and Dmc1 in Entamoeba Histolytica: Homologous Recombinases with Drug Target Potential
    Clemson University TigerPrints All Theses Theses August 2020 Investigating Rad51 and Dmc1 in Entamoeba histolytica: Homologous Recombinases with Drug Target Potential Rachel Evelyn Ham Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_theses Recommended Citation Ham, Rachel Evelyn, "Investigating Rad51 and Dmc1 in Entamoeba histolytica: Homologous Recombinases with Drug Target Potential" (2020). All Theses. 3392. https://tigerprints.clemson.edu/all_theses/3392 This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized administrator of TigerPrints. For more information, please contact [email protected]. INVESTIGATING RAD51 AND DMC1 IN ENTAMOEBA HISTOLYTICA: HOMOLOGOUS RECOMBINASES WITH DRUG TARGET POTENTIAL A Thesis Presented to the Graduate School of Clemson University In Partial Fulfillment of the Requirements for the Degree Master of Science Microbiology by Rachel Evelyn Ham August 2020 Accepted by: Dr. Lesly A. Temesvari, Committee Chair Dr. James C. Morris Dr. Yanzhang Wei ABSTRACT Entamoeba histolytica is the causative agent of amebic dysentery and is prevalent in developing countries. It has a biphasic lifecycle: active, virulent trophozoites and dormant, environmentally-stable cysts. Only cysts are capable of establishing new infections, and are spread by fecal deposition. Many unknown factors influence stage conversion, and synchronous encystation of E. histolytica is not currently possible in vitro. E. histolytica infections are treated with nitroimidazole drugs, such as metronidazole (Flagyl™). However, several clinical isolates have shown metronidazole resistance. Enhancing the amebicidal mechanisms of metronidazole through drug combination therapy may allow for more effective treatment.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Treatment of Dysentery
    Treatment of Dysentery 2-Antimicrobial agents: 1-Maintain fluid intake using: used against the two most common causes which are oral rehydration therapy or intravenous fluid therapy A-Amebic dysentery (protozoal B-Bacillary dysentery infection mainly by Entameba (bacterial infection mainly by Histolytica). shigella). ANTIAMEBIC DRUGS 1-Fluoroquinolones e.g: Ciprofloxacin 2-Cotrimoxazole (trimethoprim and sulfamethoxazole) A- Luminal Amebicides B-Tissue or systemic amebicides 3-Ceriaxone and cefixime 1-Diloxanide furoate 1-Metronidazole 2-Iodoquinol 2-Tinidazole 3-Antibiotics 3-Emetine +Dehydroemetine Paromomycin+Tetracyclin 5-Chloroquine (liver only) ANTIAMEBIC DRUGS : A- Luminal Amebicides Drugs Diloxanide furoate Iodoquino Paromomycin MOA unknown unknown *Has direct amebicidal action(causes leakage by its action on cell membrane of parasite) * Indirect killing of bacterial flora essential for proliferation of pathogenic amoebae. P.K § Ester of diloxanide + furoic acid § Is given orally § Aminoglycoside antibiotic. + § Given orally. § Not absorbed (90%), excreted in feces. § It is given orally and Not absorbed from GIT other features § It splits in tHe intestine, most of diloxanide is absorbed, § 10% enter circulation, excreted as glucouronide in urine. § Effective against luminal forms of ameba conjugated to form a glucoronide wHich is excreted in § effective against the luminal tropHozoites. § Small amount absorbed is excreted unchanged in urine (90%). urine (may accumulate with renal insufficiency) § The unabsorbed diloxanide is the amoebicidal agent (10%). § Direct amoebicidal action against luminal forms. § NOT active against trophozoites in(intestinal wall or extra-intestinal tissues) USES 1-Drug of choice for asymptomatic intestinal infection 1-luminal amoebicide for asymptomatic amebiasis 1-in chronic amebiasis to eliminate cysts , in cysts (drug of choice in cysts passers).
    [Show full text]
  • Antiprotozoal Activity Against Entamoeba Histolytica of Plants Used in Northeast Mexican Traditional Medicine. Bioactive Compoun
    Molecules 2014, 19, 21044-21065; doi:10.3390/molecules191221044 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Antiprotozoal Activity against Entamoeba histolytica of Plants Used in Northeast Mexican Traditional Medicine. Bioactive Compounds from Lippia graveolens and Ruta chalepensis Ramiro Quintanilla-Licea 1,*, Benito David Mata-Cárdenas 2, Javier Vargas-Villarreal 3, Aldo Fabio Bazaldúa-Rodríguez 1, Isvar Kavim Ángeles-Hernández 1, Jesús Norberto Garza-González 3 and Magda Elizabeth Hernández-García 3 1 Universidad Autónoma de Nuevo León, UANL, Facultad de Ciencias Biológicas, Av. Universidad S/N, Cd. Universitaria, San Nicolás de los Garza, C.P. 66451 Nuevo León, Mexico; E-Mails: [email protected] (A.F.B.-R.); [email protected] (I.K.Á.-H) 2 Universidad Autónoma de Nuevo León, UANL, Facultad de Ciencias Químicas, Av. Universidad S/N, Cd. Universitaria, San Nicolás de los Garza, C.P. 66451 Nuevo León, Mexico; E-Mail: [email protected] 3 Laboratorio de Bioquímica y Biología Celular, Centro de Investigaciones Biomédicas del Noreste (CIBIN), Dos de abril esquina con San Luis Potosí, C.P. 64720 Monterrey, Mexico; E-Mails: [email protected] (J.V.-V.); [email protected] (J.N.G.-G.); [email protected] (M.E.H.-G.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +52-81-8376-3668; Fax: +52-81-8352-5011. External Editor: Thomas J. Schmidt Received: 12 September 2014; in revised form: 10 December 2014 / Accepted: 11 December 2014 / Published: 15 December 2014 Abstract: Amoebiasis caused by Entamoeba histolytica is associated with high morbidity and mortality is becoming a major public health problem worldwide, especially in developing countries.
    [Show full text]
  • Parasitic Infections (1 of 14)
    Parasitic Infections (1 of 14) 1 Patient presents w/ signs & symptoms suggestive of GI parasitic infection 2 DIAGNOSIS No ALTERNATIVE Is a GI parasitic infection DIAGNOSIS confi rmed? Yes Protozoal or helminthic infection? Protozoal Infection Helminthic Infection A Rehydration & nutrition B Prevention PHARMACOLOGICAL PHARMACOLOGICAL THERAPY FOR THERAPY FOR PROTOZOAL HELMINTHIC INFECTIONS INFECTIONS ©See page 3 MIMSSee page 3 B1 © MIMS 2019 Parasitic Infections (2 of 14) 1 SIGNS & SYMPTOMS OF GI PARASITIC INFECTIONS GI Symptoms • Abdominal pain, diarrhea, dysentery, fl atulence, malabsorption, symptoms of biliary obstruction Nonspecifi c Symptoms • Fever, malaise, fatigue, anorexia, sweating, wt loss, edema & pruritus • Some patients may be asymptomatic PARASITIC INFECTIONS PARASITIC 2 DIAGNOSIS Clinical History • Attempt to elicit a history of possible exposure, especially for helminthic infections, eg eating undercooked meat, source of drinking water, swimming in fresh water where certain parasites may be endemic • Knowledge of the geographic distribution of parasites is helpful in the diagnosis of patients Host Susceptibility Factors in GI Parasitic Infections • Nutritional status • Intercurrent disease • Pregnancy • Immunosuppressive drugs • Presence of a malignancy Physical Exam Findings • Pallor • Hepatomegaly • Ascites • Ileus • Rectal prolapse Lab Tests Microscopic Exam of Stools • Fundamental to the diagnosis of all GI infections - A minimum of 3 stool specimens, examined by trained personnel using a concentration & a permanent stain
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Simaroubaceae Family: Botany, Chemical Composition and Biological Activities
    Rev Bras Farmacogn 24(2014): 481-501 Review Simaroubaceae family: botany, chemical composition and biological activities Iasmine A.B.S. Alvesa, Henrique M. Mirandab, Luiz A.L. Soaresa,b, Karina P. Randaua,b,* aLaboratório de Farmacognosia, Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Federal de Pernambuco, Recife, PE, Brazil bLaboratório de Farmacognosia, Departamento de Farmácia, Universidade Federal de Pernambuco, Recife, PE, Brazil ARTICLE INFO ABSTRACT Article history: The Simaroubaceae family includes 32 genera and more than 170 species of trees and Received 20 May 2014 brushes of pantropical distribution. The main distribution hot spots are located at tropical Accepted 10 July 2014 areas of America, extending to Africa, Madagascar and regions of Australia bathed by the Pacific. This family is characterized by the presence of quassinoids, secondary metabolites Keywords: responsible of a wide spectrum of biological activities such as antitumor, antimalarial, an- Chemical constituents tiviral, insecticide, feeding deterrent, amebicide, antiparasitic and herbicidal. Although the Simaba chemical and pharmacological potential of Simaroubaceae family as well as its participa- Simarouba tion in official compendia; such as British, German, French and Brazilian pharmacopoeias, Simaroubaceae and patent registration, many of its species have not been studied yet. In order to direct Quassia further investigation to approach detailed botanical, chemical and pharmacological aspects of the Simaroubaceae, the present work reviews
    [Show full text]
  • WO 2016/033635 Al 10 March 2016 (10.03.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/033635 Al 10 March 2016 (10.03.2016) P O P C T (51) International Patent Classification: AN, Martine; Epichem Pty Ltd, Murdoch University Cam Λ 61Κ 31/155 (2006.01) C07D 249/14 (2006.01) pus, 70 South Street, Murdoch, Western Australia 6150 A61K 31/4045 (2006.01) C07D 407/12 (2006.01) (AU). ABRAHAM, Rebecca; School of Animal and A61K 31/4192 (2006.01) C07D 403/12 (2006.01) Veterinary Science, The University of Adelaide, Adelaide, A61K 31/341 (2006.01) C07D 409/12 (2006.01) South Australia 5005 (AU). A61K 31/381 (2006.01) C07D 401/12 (2006.01) (74) Agent: WRAYS; Groud Floor, 56 Ord Street, West Perth, A61K 31/498 (2006.01) C07D 241/20 (2006.01) Western Australia 6005 (AU). A61K 31/44 (2006.01) C07C 211/27 (2006.01) A61K 31/137 (2006.01) C07C 275/68 (2006.01) (81) Designated States (unless otherwise indicated, for every C07C 279/02 (2006.01) C07C 251/24 (2006.01) kind of national protection available): AE, AG, AL, AM, C07C 241/04 (2006.01) A61P 33/02 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07C 281/08 (2006.01) A61P 33/04 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07C 337/08 (2006.01) A61P 33/06 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07C 281/18 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/AU20 15/000527 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (22) International Filing Date: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 28 August 2015 (28.08.2015) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]